Payment overview · 2025
General Payments
$5,023.33
148 reported records · 29 companies
Healthcare provider profile · identity verified
Luis Ignacio Becerra-Cabal, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · AVENTURA, FL · NPI 1164493649
Verified facts
What the public records show
CMS Open Payments records show Luis Ignacio Becerra-Cabal, M.D. received $5,023.33 in general payments during 2025 across 148 reported records.
PFIZER INC. accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Nurtec Odt, Qulipta, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nuplazid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gocovri by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $1,771.79 | 35.3% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $639.78 | 12.7% | 36 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $256.60 | 5.1% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $237.89 | 4.7% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $182.95 | 3.6% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $170.29 | 3.4% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $166.15 | 3.3% | 5 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $161.65 | 3.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $137.87 | 2.7% | 5 | 2025 |
| MicroVention, Inc. | Unresolved — no canonical attribution shown | $133.08 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.63 | 2.4% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$111.78 | 2.2% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $109.32 | 2.2% | 6 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $85.83 | 1.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.21 | 1.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $81.95 | 1.6% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $78.34 | 1.6% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $67.77 | 1.4% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $67.72 | 1.4% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $53.01 | 1.1% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $50.72 | 1.0% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.20 | 1.0% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $48.03 | 1.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $38.32 | 0.8% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $28.81 | 0.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.27 | 0.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.76 | 0.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.53 | 0.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $15.08 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,399.33 | 146 |
| Consulting Fee | $1,525.00 | 1 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $1,771.79 | 15 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $418.25 | 13 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $323.99 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $271.24 | 18 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $254.85 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $200.33 | 12 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $182.95 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $170.03 | 13 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $137.87 | 5 | 2025 |
Source payment records
|
|||||
| WEB ANEURYSM EMBOLIZATION SYSTEM Normalized: web aneurysm embolization system |
Device | MicroVention, Inc. | $133.08 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $85.83 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $83.21 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $81.95 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $81.59 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $78.34 | 3 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $77.21 | 5 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $68.63 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $67.72 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $48.20 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $38.32 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $34.23 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $33.54 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 48 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 175 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 69 |
| Gabapentin | Gabapentin | 145 | 62 |
| Sertraline Hcl | Sertraline Hcl | 117 | 36 |
| Donepezil Hcl | Donepezil Hcl | 77 | 29 |
| Pregabalin | Pregabalin | 74 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 19 |
| Primidone | Primidone | 64 | 21 |
| Levetiracetam | Levetiracetam | 63 | 21 |
| Nurtec Odt | Rimegepant Sulfate | 48 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 19 |
| Neupro | Rotigotine | 45 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | 17 |
| Emgality Pen | Galcanezumab-Gnlm | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 19 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Gocovri | Amantadine Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,023.33 · 148 records | PFIZER INC. | AUSTEDO XR, Apokyn, BOTOX, CREXONT, Fintepla, INGREZZA, KESIMPTA, LEQEMBI, NUPLAZID, NURTEC ODT, Ocrevus, Ocrevus Zunovo, PONVORY, QULIPTA, REXULTI, Radicava, Senza, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WEB ANEURYSM EMBOLIZATION SYSTEM, Xeomin, ZAVZPRET, Zilbrysq | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error